In comparison, the relatively narrow range of IPO11 cargo, as demonstrated by our BioID studies and their overexpression in AML cells and stem cells may make IPO11 or its cargo a more favorable therapeutic target. Here, IPO11 is linked to acute myeloid leukemia.